Yahoo
NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

70.14 +1.49 (+2.17%)
At close: June 26 at 4:00:01 PM EDT
69.95 -0.19 (-0.27%)
Pre-Market: 4:01:04 AM EDT
Trade DexCom on Coinbase
Chart Range Bar
Loading chart for DXCM

News headlines DexCom is advancing its glucose monitoring technology with FDA clearance for its Stelo Glucose Biosensor for children and a redesigned app launch. Despite a 45% declineover three years, analysts see potential value with an intrinsic target of $117.40per share, suggesting the stock may be undervalued.

DexCom is advancing its glucose monitoring technology with FDA clearance for its Stelo Glucose Biosensor for children and a redesigned app launch. Despite a 45% declineover three years, analysts see potential value with an intrinsic target of $117.40per share, suggesting the stock may be undervalued.

Updated 18m ago · Powered by Yahoo Scout
  • Previous Close 68.65
  • Open 68.62
  • Bid 64.11 x 100
  • Ask 74.89 x 100
  • Day's Range 68.28 - 70.38
  • 52 Week Range 54.11 - 89.98
  • Volume 6,872,596
  • Avg. Volume 5,620,232
  • Market Cap (intraday) 27.065B
  • Beta (5Y Monthly) 1.44
  • PE Ratio (TTM) 30.10
  • EPS (TTM) 2.33
  • Earnings Date (est.) Jul 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 85.24

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

www.dexcom.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 6/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DXCM
5.68%
S&P 500 (^GSPC)
7.43%

1-Year Return

DXCM
17.52%
S&P 500 (^GSPC)
19.75%

3-Year Return

DXCM
43.72%
S&P 500 (^GSPC)
69.89%

5-Year Return

DXCM
34.81%
S&P 500 (^GSPC)
71.79%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.19B
Earnings 216.3M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
200M
400M
600M
800M
1B
1B

Analyst Insights

View More

Analyst Price Targets

65.00
85.24 Average
70.14 Current
112.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/23/2026
Analyst Deutsche Bank
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 86

Statistics

View More

Valuation Measures

Annual
As of 6/26/2026
  • Market Cap

    27.07B

  • Enterprise Value

    26.03B

  • Trailing P/E

    30.10

  • Forward P/E

    27.40

  • PEG Ratio (5yr expected)

    1.31

  • Price/Sales (ttm)

    5.85

  • Price/Book (mrq)

    9.15

  • Enterprise Value/Revenue

    5.40

  • Enterprise Value/EBITDA

    17.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.31%

  • Return on Assets (ttm)

    9.65%

  • Return on Equity (ttm)

    35.62%

  • Revenue (ttm)

    4.82B

  • Net Income Avi to Common (ttm)

    930.4M

  • Diluted EPS (ttm)

    2.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.42B

  • Total Debt/Equity (mrq)

    46.83%

  • Levered Free Cash Flow (ttm)

    1.06B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

70.14 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Lowering target price to $22.00

    TRUPANION INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
  • Raising target price to $23.00

    TRUPANION INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
  • What does Argus have to say about TRUP?

    TRUPANION INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
  • What does Argus have to say about TRUP?

    TRUPANION INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: